Cargando…
Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy
The discovery of highly active antiretroviral therapy (HAART) in 1996 has significantly reduced the global mortality and morbidity caused by the acquired immunodeficiency syndrome (AIDS). However, the therapeutic strategy of HAART that targets multiple viral proteins may render off-target toxicity a...
Autores principales: | Che Nordin, Muhamad Alif, Teow, Sin-Yeang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017373/ https://www.ncbi.nlm.nih.gov/pubmed/29415435 http://dx.doi.org/10.3390/molecules23020335 |
Ejemplares similares
-
Exosomes in Human Immunodeficiency Virus Type I Pathogenesis: Threat or Opportunity?
por: Teow, Sin-Yeang, et al.
Publicado: (2016) -
Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?
por: Awi, Noel Jacques, et al.
Publicado: (2018) -
A Cell Internalizing Antibody Targeting Capsid Protein (p24) Inhibits the Replication of HIV-1 in T Cells Lines and PBMCs: A Proof of Concept Study
por: Ali, Syed A., et al.
Publicado: (2016) -
Engineering and Validation of a Vector for Concomitant Expression of Rare Transfer RNA (tRNA) and HIV-1 nef Genes in Escherichia coli
por: Mualif, Siti Aisyah, et al.
Publicado: (2015) -
Production and purification of polymerization-competent HIV-1 capsid protein p24 (CA) in NiCo21(DE3) Escherichia coli
por: Teow, Sin Yeang, et al.
Publicado: (2013)